Return to Home Page

American Myalgic Encephalomyelitis and
Chronic Fatigue Syndrome Society

ABOUT ME/CFS
TREATMENT
GET SUPPORT
FIND A PHYSICIAN
- How to Talk to Your Doctor
- Physician and Clinic Database
GET INVOLVED
RESOURCES
ABOUT US

Normodyne (labetalol) Rating

Please only submit a rating once.

How satisfied were you with normodyne-labetalol?

5 – Very satisfied. This treatment was very helpful.

4 – Satisfied. This treatment helped.

3 – Somewhat satisfied. This treatment helped somewhat. I may try it again.

2 – Not satisfied. This treatment was not helpful.

1 – Dissatisfied. I had a bad experience with this treatment. I would never try it again.

Dosage (such as 30 mg)

Frequency

Times per

Length of time taking this treatment

Sex

M F

Age

Years ill – pick the closest number

Why were you taking normodyne-labetalol? (Please be brief.)
Briefly describe any side effects you experienced.
Additional Comments
Please indicate your illness severity. (Check the box that was closest to you when you were being treated)

Severe = I can’t get out of bed and need help taking care of my personal needs.

Moderate/Severe = I am housebound. I can do light housekeeping.

Moderate = I can drive, go shopping, and do some part-time work.

Moderate/Mild = I can work part time and do some socializing.

Mild = I can work full time. My social life is curtailed, and I have to be careful not to overdo.

Help us continue our mission!

Breaking News

AMMES WANTS YOU!
AMMES needs volunteers! AMMES is actively recruiting volunteers to help AMMES grow and prosper. Fundraising coordinator – should have experience …Read More »
WE WANT TO HELP!
Getting help is a priority for people who are ill. This is especially important for ME/CFS patients who have lost their …Read More »
Covid and ME/CFS
Announcement: AMMES has recently added an informational page about COVID-19 and ME/CFS. The page includes physicians’ recommendations regarding the COVID …Read More »
Mitochondrial dysfunction in long COVID: mechanisms, consequences, and potential therapeutic approaches
Abstract: The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has introduced the medical community to the phenomenon of long COVID, …Read More »
Multimodal treatment strategies for homebound people with severe ME/CFS: a scoping review
Abstract: Purpose: This scoping review aims to provide an overview of previously published treatment strategies that are multimodal, rather than purely …Read More »
Mitochondrial DNA Missense Mutations ChrMT: 8981A > G and ChrMT: 6268C > T Identified in a Caucasian Female with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Triggered by the Epstein–Barr Virus
Abstract: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a multisystem disabling disease with unclear etiology and pathophysiology, whose typical symptoms include …Read More »
Oxidative Stress is a shared characteristic of ME/CFS and Long COVID
Abstract: More than 65 million individuals worldwide are estimated to have Long COVID (LC), a complex multisystemic condition, wherein patients …Read More »
Long COVID: lights and shadows on the clinical characterization of this emerging pathology
Abstract: More than 800 million individuals have contracted SARSCOV2 infection worldwide. It was estimated that almost 10-20% of these might …Read More »

This site uses functional cookies and external scripts to improve your experience.

Privacy settings

Privacy Settings

This site uses functional cookies and external scripts to improve your experience. Which cookies and scripts are used and how they impact your visit is specified on the left. You may change your settings at any time. Your choices will not impact your visit.

NOTE: These settings will only apply to the browser and device you are currently using.

Google Analytics

This website uses cookies that do not collect personal information but that do help us collect anonymous information about how people use our website. We use Google Analytics for this purpose. Google Analytics generates statistical and other information about website usage by means of cookies, which are stored on users’ computers. The information collected by Google Analytics about usage of our website is not personally identifiable. The data is collected anonymously, stored by Google and used by us to create reports about website usage.

Help us continue our mission!

The American ME and CFS Society

ABOUT ME/CFS

What Is ME/CFS?
What Causes ME/CFS?
Symptoms of ME/CFS
How Many People Have ME/CFS?
How Is ME/CFS Diagnosed?
Overlapping Conditions
Will I Recover?
ME/CFS in Adolescents
ME/CFS in Children
ME/CFS: Facts & Myths
FAQs
Outbreaks
Anesthesia Warning

TREATMENT

Treatment Overview
Pharmaceuticals
Supplements
Alternative and Complementary Therapies
Experimental Treatments
Diet
Exercise
Coping Strategies
Pacing
Treatment Database

GET SUPPORT

Organizations
Find a Support Group
Work and Disability
Relationships
For Caregivers
AMMES Connect
Financial Crisis Fund

FIND A PHYSICIAN

How to Talk to Your Doctor
Physician and Clinic Database

GET INVOLVED

Why We Need Advocacy
Advocacy Groups
Action Alerts!
Volunteer
Donate
Clinical Trials

RESOURCES

Blogs
Videos and DVDs
Books
For Clinicians
Useful Links
News and Research
Interviews With Doctors
Newsletters
COVID-19 and ME/CFS

ABOUT US

What We Do
Who We Are
Policies and Disclaimer
AMMES By-Laws
Privacy Policy

Join Us

The American ME and CFS Society is a 501(c)(3) nonprofit

This site is not intended as a substitute for medical care. The American ME and CFS Society is not responsible or liable for actions taken as a result of the information presented on this website. Please consult a clinician before embarking on any medical treatment, therapy, or program.